Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

Br J Haematol. 2014 Nov;167(3):418-20. doi: 10.1111/bjh.12985. Epub 2014 Jun 25.
No abstract available

Keywords: CALR; JAK inhibition; myeloproliferative disease.

Publication types

  • Letter
  • Practice Guideline

MeSH terms

  • Anemia / chemically induced
  • Humans
  • Janus Kinase 1 / antagonists & inhibitors*
  • Janus Kinase 2 / antagonists & inhibitors*
  • Maximum Tolerated Dose
  • Primary Myelofibrosis / complications
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / enzymology
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Recurrence
  • Splenomegaly / drug therapy
  • Splenomegaly / etiology
  • Symptom Assessment
  • Thrombocytopenia / chemically induced

Substances

  • INCB018424
  • Protein Kinase Inhibitors
  • Pyrazoles
  • JAK2 protein, human
  • Janus Kinase 1
  • Janus Kinase 2